Nephros Stock Today
| NEPH Stock | USD 1.63 0.01 0.62% |
PerformanceInsignificant
| Odds Of DistressVery High
|
Nephros is trading at 1.63 as of the 16th of March 2025. This is a 0.62 percent increase since the beginning of the trading day. The stock's open price was 1.62. Nephros has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Consumer Durables & Apparel | IPO Date 21st of September 2004 | Category Healthcare | Classification Consumer Discretionary |
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Nephros operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. The company has 10.54 M outstanding shares of which 9.57 K shares are now shorted by private and institutional investors with about 0.44 trading days to cover. More on Nephros
Moving against Nephros Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Nephros Stock Highlights
| CEO | Daron Evans | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Medical Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Household Appliances, Medical Instruments & Supplies, Consumer Discretionary, NASDAQ Composite, NASDAQ Health Care, Medical Equipment, Consumer Discretionary, Household Durables, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNephros can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Nephros' financial leverage. It provides some insight into what part of Nephros' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nephros (NEPH) is traded on NASDAQ Exchange in USA. It is located in 380 Lackawanna Place, South Orange, NJ, United States, 07079 and employs 11 people. Nephros is listed under Household Appliances category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.19 M. Nephros conducts business under Household Durables sector and is part of Consumer Discretionary industry. The entity has 10.54 M outstanding shares of which 9.57 K shares are now shorted by private and institutional investors with about 0.44 trading days to cover.
Nephros currently holds about 4.18 M in cash with 827 K of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Check Nephros Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Nephros is $17.19 Million. 30% of Nephros outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Nephros Ownership Details
Nephros Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Mesirow Fin Investmt Mgmt Intl Equity | 2024-12-31 | 13.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 5.4 K | |
| Tower Research Capital Llc | 2024-12-31 | 2.6 K | |
| Bank Of America Corp | 2024-12-31 | 76.0 | |
| Jpmorgan Chase & Co | 2024-12-31 | 15.0 | |
| Royal Bank Of Canada | 2024-12-31 | 2.0 | |
| Granite Investment Partners, Llc | 2024-09-30 | 0.0 | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 0.0 | |
| Renaissance Technologies Corp | 2024-12-31 | 0.0 | |
| Wexford Capital Lp | 2024-12-31 | 3.6 M | |
| Vanguard Group Inc | 2024-12-31 | 202 K |
Nephros Historical Income Statement
Nephros Stock Against Markets
Nephros Corporate Management
| Vashone Thomas | Regulatory, Quality | Profile | |
| Joleen Turner | VP Devel | Profile | |
| Judy CFA | Chief Officer | Profile | |
| Judy Mazzini | Controller | Profile | |
| MS MBA | Inc Products | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Household Appliances space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.01 | Revenue Per Share | Quarterly Revenue Growth 0.189 | Return On Assets | Return On Equity |
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.